American Gene Technologies

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
AGT is a gene and cell therapy company working in immuno-oncology, infectious disease, and rare disease.

AGT recently submitted the Investigational New Drug (IND) document to the FDA for an HIV Cure program. The upcoming Phase I open-label trial of AGT’s autologous cell therapy is expected to demonstrate safety and efficacy readouts over the next nine months. Success in this study will be highly disruptive to the HIV market, and create an important commercial asset for AGT.

AGT’s HIV program is the near-term liquidity opportunity, in addition to lead programs in phenylketonuria (PKU) and immuno-oncology (I/O).
Company Type:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
AGT103-T - HIV cure program
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
American Gene Technologies